Giuseppe Lombardi, Head of the Neuro-Oncology Unit at the Veneto Institute of Oncology, shared a post on LinkedIn:
“Neuro-Oncology Non-Stop! World Neuro-Oncology Congress!”
Results from the phase 1 REGOMA2 trial (regorafenib + RT + TMZ) in newly diagnosed GBM showed good tolerability and very promising preliminary outcomes (mOS ~37 months, mPFS ~18 months). Ready for the phase 2!”
More posts featuring Giuseppe Lombardi.